Repositioning Candidate Details
| Candidate ID: | R1439 |
| Source ID: | DB12243 |
| Source Type: | approved; investigational |
| Compound Type: | small molecule |
| Compound Name: | Edaravone |
| Synonyms: | 1-phenyl-3-methyl-5-oxo-2-pyrazoline; 2,4-dihydro-5-methyl-2-phenyl-3H-pyrazol-3-one; 3-methyl-1-phenyl-2-pyrazolin-5-one; 3-methyl-1-phenyl-5-pyrazolone; 3-methyl-1-phenylpyrazol-5-one; Edaravone; Methylphenylpyrazolone; Norphenazone; Phenyl methyl pyrazolone; Phenylmethylpyrazolone |
| Molecular Formula: | C10H10N2O |
| SMILES: | CC1=NN(C(=O)C1)C1=CC=CC=C1 |
| Structure: |
|
| DrugBank Description: | Edaravone is a free radical scavenger approved in May, 2017 for the treatment of amyotrophic lateral scleorosis (ALS). Clinical studies showed that the treatment attenuated deterioration of the disease when compared to placebo. It has been previously investigated for the treatment of ischemic stroke, reperfusion Injury, and myocardial Infarction as it possesses antioxidant and anti-apoptotic properties. Being a low molecular weight molecule with good water and lipid-soluble properies, it is therapeutically advantageous in crossing the blood-brain barrier to mediate nootropic and neuroprotective effects. Oral formulation of edaravone is currently under development. |
| CAS Number: | 89-25-8 |
| Molecular Weight: | 174.203 |
| DrugBank Indication: | Indicated for improving neurological symptoms and damage from acute ischemic stroke and delaying disease progression of ALS. |
| DrugBank Pharmacology: | Edaravone scavenges free hydroxyl radicals and peroxynitrite radicals which are highly associated with neuronal damage/death from many cerebral vascular disorders such as ischemic strokes and degenerative neurological disorders such as ALS. It exerts a neuroprotective and antioxidant effect and delays disease progression by limiting the extent of lipid peroxidation via free radical generation and cell membrane damage from oxidative stress. It reversed the reduction in regional blood flow and cerebral edema in a case of ischemic stroke. |
| DrugBank MoA: | Nootropic and neuroprotective effects are mediated through inhibiting lipid peroxidation and scavenging free radicals. Edaravone acts to increase prostacyclin production, decrease lipoxygenase metabolism of arachidonic acid by trapping hydroxyl radicals, and inhibit alloxan-induced lipid peroxidation and quench active oxygen species. It targets various kinds of cells, including neurons, endothelial cells and myocardial cells . There is also evidence of reduction of neuronal nitric oxide synthase (nNOS) levels and potentiation of SOD1 levels after transient ischemia in rabbits thus preventing spinal cord injury. |
| Targets: | -- |
| Inclusion Criteria: | Therapeutic strategy associated |
| Diseases ID | DO ID | Disease Name | Definition | Class | |
|---|---|---|---|---|---|
| I08 | 114 | Cardiovascular system disease | A disease of anatomical entity which occurs in the blood, heart, blood vessels or the lymphatic system that passes nutrients (such as amino acids and electrolytes), gases, hormones, blood cells or lymph to and from cells in the body to help fight diseases and help stabilize body temperature and pH to maintain homeostasis. http://en.wikipedia.org/wiki/Circulatory_system | disease of anatomical entity | Details |
| I16 | 6713 | Cerebrovascular disease | An vascular disease that is characterized by dysfunction of the blood vessels supplying the brain. http://en.wikipedia.org/wiki/Cerebrovascular_disease, http://www.ncbi.nlm.nih.gov/books/NBK378/ | disease of anatomical entity/ cardiovascular system disease/ vascular disease/cerebrovascular disease | Details |